CBA Pharmaceuticals

CBA Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies to overcome multi-drug resistance (MDR) in cancer patients. The company's lead candidate, CBA-120, is a potent small molecule inhibitor of P-glycoprotein (P-gp), a protein often responsible for pumping chemotherapy drugs out of cancer cells. By inhibiting this efflux pump, CBA Pharmaceuticals aims to restore the efficacy of standard chemotherapeutic agents in resistant populations. The company is primarily targeting indications such as acute myeloid leukemia (AML) and various solid tumors where MDR remains a significant clinical challenge.